.Pharmacolibrary.Drugs.ATC.H.H05BX04 .Pharmacolibrary.Drugs.ATC.H.H05BX04| name: | Etelcalcetide |
| ATC code: | H05BX04 | route: | intravenous |
| n-compartments | 2 |
Etelcalcetide is a synthetic peptide calcimimetic agent used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) on hemodialysis. It acts as an agonist of the calcium-sensing receptor on parathyroid cells, thereby lowering parathyroid hormone (PTH) levels. Etelcalcetide is approved and currently used clinically.
Pharmacokinetic parameters reported for adult patients with end-stage renal disease on hemodialysis, following intravenous administration.
Wu, B, et al., & Lee, E (2018). Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis. Journal of clinical pharmacology 58(6) 717–726. DOI:10.1002/jcph.1090 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29534286
Chen, P, et al., & Melhem, M (2018). Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. Clinical pharmacokinetics 57(1) 71–85. DOI:10.1007/s40262-017-0550-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28508378
Sohn, W, et al., & Warady, BA (2021). Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis. Pediatric nephrology (Berlin, Germany) 36(1) 133–142. DOI:10.1007/s00467-020-04599-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/32647975